<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Novo says Wegovy injection lowers BMI and obesity rates in children in trial — Live Feed</title><link>https://www.live-feeds.com/feed/novo-says-wegovy-injection-lowers-bmi-and-obesity-rates-in-children-in-trial</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/novo-says-wegovy-injection-lowers-bmi-and-obesity-rates-in-children-in-trial/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Novo Nordisk reports Wegovy lowers BMI and obesity in children as young as six in trial</title><link>https://www.live-feeds.com/feed/novo-says-wegovy-injection-lowers-bmi-and-obesity-rates-in-children-in-trial</link><guid isPermaLink="false">https://www.live-feeds.com/feed/novo-says-wegovy-injection-lowers-bmi-and-obesity-rates-in-children-in-trial#u209333</guid><pubDate>Thu, 19 Nov 2026 22:05:09 +0000</pubDate><description>Novo Nordisk said its Wegovy injection reduced body mass index and obesity rates in children in a clinical trial, according to company reporting covered by CNBC, Quartz, WSJ, Financial Times and The New York Times. The New York Times and Financial Times identified the studied group as children as young as six years old. CNBC, Quartz and WSJ headline the trial results as successful. Separately, Reuters reported real-world data showing adults taking Novo&amp;#039;s Wegovy pill lost about six percent of body weight over three months. Doctors remain divided on how widely GLP-1 drugs should be used in </description></item>
</channel></rss>